This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 12496 results found since Jan 2013.
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
Conditions: Opioid-Related Disorders; Substance-Related Disorders; Narcotic-Related Disorders Interventions: Drug: Injectable extended-release buprenorphine; Drug: Sublingual buprenorphine-naloxone Sponsors: Yih-Ing Hser; National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); The Emmes Company, LLC; University of California, Los Angeles; RAND; Cornell University; Oregon Health and Science University; University of Illinois at C hicago; University of Washington; West Virginia University Not yet recruiting
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials
Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes
ConclusionsOur findings suggest that telehealth-initiated buprenorphine treatment is associated with reduced opioid overdose rate and improved patient engagement. Our findings strengthen the case for extending telehealth exemptions and prescribing flexibilities for treatment.
Source: Journal of General Internal Medicine - September 5, 2023 Category: Internal Medicine Source Type: research
The Solution to Telemedicine Prescribing of Buprenorphine Seems Clear to Everyone but DEA
For more than a decade, Congress, clinicians, and policymakers have been requesting implementation of a special registration pathway that would allow registered clinicians to prescribe buprenorphine without an in-person visit requirement. It ' s clear to us that the time to implement the pathway is now.
Source: The RAND Blog - September 5, 2023 Category: Health Management Authors: Lori Uscher-Pines Source Type: blogs
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
Conditions: Opioid-Related Disorders; Substance-Related Disorders; Narcotic-Related Disorders Interventions: Drug: Injectable extended-release buprenorphine; Drug: Sublingual buprenorphine-naloxone Sponsors: Yih-Ing Hser; National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); The Emmes Company, LLC; University of California, Los Angeles; RAND; Cornell University; Oregon Health and Science University; University of Illinois at C hicago; University of Washington; West Virginia University Not yet recruiting
Source: ClinicalTrials.gov - September 4, 2023 Category: Research Source Type: clinical trials
Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use
CONCLUSIONS: PWH with OUD spend relatively little time receiving buprenorphine in their HIV primary care clinic. Concurrent cocaine use at buprenorphine initiation negatively impact time on buprenorphine.PMID:37660116 | PMC:PMC10474763 | DOI:10.1186/s13722-023-00408-8
Source: Addiction Science and Clinical Practice - September 2, 2023 Category: Addiction Authors: Jarratt D Pytell Anthony T Fojo Jeanne C Keruly LaQuita N Snow Oluwaseun Falade-Nwulia Richard D Moore Geetanjali Chander Catherine R Lesko Source Type: research
Availability of telehealth-based services at syringe services programs under the COVID-19 Public Health Emergency
The expanded capacity of syringe services programs (SSPs) in the USA to integrate telehealth services was largely related to flexibility of buprenorphine prescription in response to the COVID-19 pandemic. SSPs...
Source: Harm Reduction Journal - September 2, 2023 Category: Drugs & Pharmacology Authors: Tyler S. Bartholomew, Hansel E. Tookes, Teresa A. Chueng, Ricky N. Bluthenthal, Lynn D. Wenger, Alex H. Kral and Barrot H. Lambdin Tags: Research Source Type: research
Substance Use Disorder and Health Outcomes in COVID-19 —The Need for a Better Research Method to Determine Substance Use Exposure—Reply
In Reply We thank Christian et al for raising concerns that (1) chronic diseases, rather than substance use disorder (SUD), may be more directly responsible for adverse outcomes of COVID-19 infection and (2) SUD itself can cause chronic somatic and mental health disorders. Both concerns are valid and important. These suggest new directions for research to describe the relative impact of chronic diseases and SUD on outcomes of COVID-19 infection. We agree that a better understanding of how medications prescribed for opioid use disorder (eg, methadone or buprenorphine) alter COVID-19 risk among persons with this SUD would be...
Source: JAMA Psychiatry - September 1, 2023 Category: Psychiatry Source Type: research
American Lung Association Wants to Keep Smokers Misinformed About the Relative Risks of Different Tobacco Products
Incomments submitted to the FDA in response to the Center for Tobacco Products ' (CTP) draft strategic plan, the American Lung Association expressed its opposition to one of the strategic goals, which was to " inform adults who smoke about the relative risks of tobacco products. " This goal primarily expressed the desire of the CTP to inform smokers that electronic cigarettes are much safer than real cigarettes and therefore may be considered as a safer alternative for smokers who are unable to quit using other cessation methods.The American Lung Association does not approve of this goal, writing: "Remove language from the...
Source: The Rest of the Story: Tobacco News Analysis and Commentary - August 31, 2023 Category: Addiction Source Type: blogs
Pronounced State Level Disparities in Medicaid Prescribing of Buprenorphine for Opioid Use Disorder (2019-2020)
CONCLUSIONS: The COVID-19 pandemic exacerbated state-level disparities in buprenorphine prescribing for OUD among Medicaid patients. Legislation expanding buprenorphine waivered providers and Medicaid expansion may have contributed to the statistically significant changes in state buprenorphine prescriptions.PMID:37650858 | DOI:10.15288/jsad.22-00373
Source: Journal of Studies on Alcohol and Drugs - August 31, 2023 Category: Addiction Authors: Sydney R Dana Stephanie D Nichols Kenneth L McCall Brian J Piper Source Type: research
